Gene: VKORC1

79001
EDTP308|MST134|MST576|VKCFD2|VKOR
vitamin K epoxide reductase complex subunit 1
protein-coding
16p11.2
Ensembl:ENSG00000167397 MIM:608547 Vega:OTTHUMG00000047408 UniprotKB:Q9BQB6
NG_011564.1
PubMed
0   ANCO-SNPs
CD|ND|AD
23   
NA (AD)  NA (ND)   (Frontal_Cortex)
5.450e-1 (AD)  4.004e-2 (ND)

DNA Methylation

Probe Locus(GRCh37) Gene Region p-val Trait PubMed ID
cg01305745chr16:31106788VKORC15.300e-9Smoking27651444

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
PPP4C0.907
LMAN20.902
TALDO10.896
RBM420.895
PPIB0.893
SEC130.892
EIF3G0.889
SCNM10.886
WDR83OS0.885
SNRPA0.885

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OR4F5-0.71
OR4F29-0.676
XIRP2-0.196
AMPD1-0.191
TBX4-0.18
MTRNR2L9-0.176
MYL1-0.165
C10orf71-0.163
MYH2-0.161
OR6C74-0.157

Drugs/Compounds

ID Drug Name Drug Type CAS Num Status Role
DB00170MenadioneSmall Molecule58-27-5Approved|NutraceuticalTarget
DB00266DicoumarolSmall Molecule66-76-2ApprovedTarget
DB00498PhenindioneSmall Molecule83-12-5Approved|InvestigationalTarget
DB00682WarfarinSmall Molecule81-81-2ApprovedTarget
DB00946PhenprocoumonSmall Molecule435-97-2Approved|InvestigationalTarget
DB01418AcenocoumarolSmall Molecule152-72-7Approved|InvestigationalTarget
DB09332KappadioneSmall Molecule131-13-5ApprovedEnzyme
ID Drug Name Action PubMed
C1111182',3,3',4',5-pentachloro-4-hydroxybiphenyl"2',3,3',4',5-pentachloro-4-hydroxybiphenyl results in decreased expression of VKORC1 mRNA"19114083
C0142112,3,7,8-tetrachlorodibenzofuran"2,3,7,8-tetrachlorodibenzofuran results in decreased expression of VKORC1 mRNA"21724226
C0294972,3-bis(3'-hydroxybenzyl)butyrolactone"[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of VKORC1 mRNA"19167446
C0164032,4-dinitrotoluene"2,4-dinitrotoluene affects the expression of VKORC1 mRNA"21346803
C0235142,6-dinitrotoluene"2,6-dinitrotoluene affects the expression of VKORC1 mRNA"21346803
C4727913-(4'-hydroxy-3'-adamantylbiphenyl-4-yl)acrylic acid3-(4'-hydroxy-3'-adamantylbiphenyl-4-yl)acrylic acid results in increased expression of VKORC1 mRNA16788091
C5767013-acetyl-5-methyltetronic acid3-acetyl-5-methyltetronic acid results in decreased activity of VKORC1 protein22322189
C0095054,4'-diaminodiphenylmethane"4,4'-diaminodiphenylmethane results in decreased expression of VKORC1 mRNA"18648102
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VKORC1 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VKORC1 mRNA"27188386
C0878377-hydroxywarfarinVKORC1 gene polymorphism affects the abundance of 7-hydroxywarfarin25986145
D000074AcenocoumarolVKORC1 gene polymorphism affects the susceptibility to Acenocoumarol16611310|1686982
D000074AcenocoumarolVKORC1 intron SNP affects the susceptibility to Acenocoumarol16201835
D000074AcenocoumarolVKORC1 polymorphism affects the susceptibility to Acenocoumarol25042728
D000074AcenocoumarolVKORC1 promoter polymorphism results in decreased susceptibility to Acenocoumarol19875892
D000074AcenocoumarolVKORC1 protein polymorphism affects the susceptibility to Acenocoumarol26757860
D000074AcenocoumarolVKORC1 protein polymorphism results in decreased susceptibility to Acenocoumarol17036862
D000074AcenocoumarolVKORC1 protein results in increased susceptibility to Acenocoumarol16869821
D000082AcetaminophenAcetaminophen affects the expression of VKORC1 mRNA17562736
D020106AcrylamideAcrylamide results in decreased expression of VKORC1 mRNA28959563
D000517alpha-Chlorohydrinalpha-Chlorohydrin results in increased expression of VKORC1 mRNA28522335
D000894Anti-Inflammatory Agents, Non-Steroidal"VKORC1 gene SNP results in increased susceptibility to Anti-Inflammatory Agents, Non-Steroidal"28338108
D000925AnticoagulantsVKORC1 protein polymorphism affects the susceptibility to Anticoagulants27196872
D000925AnticoagulantsVKORC1 protein mutant form results in decreased susceptibility to Anticoagulants19890940
D001241AspirinVKORC1 gene SNP results in increased susceptibility to Aspirin28338108
C547126AZM551248AZM551248 results in increased expression of VKORC1 mRNA22323515
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of VKORC1 mRNA20106945
D001564Benzo(a)pyreneBenzo(a)pyrene promotes the reaction [AHR protein binds to VKORC1 promoter]19654925
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of VKORC1 mRNA27195522
D003374CoumarinsCoumarins affects the activity of VKORC1 protein18278162
C006780bisphenol A[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of VKORC1 mRNA28628672
C006780bisphenol Abisphenol A results in increased expression of VKORC1 mRNA25181051
C000611646bisphenol F[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of VKORC1 mRNA28628672
C021636bromadioloneVKORC1 protein polymorphism results in decreased susceptibility to bromadiolone27117082
C021636bromadioloneVKORC1 gene mutant form results in decreased susceptibility to bromadiolone19752778
C021636bromadioloneVKORC1 gene polymorphism results in decreased susceptibility to bromadiolone17994578
C021636bromadioloneVKORC1 protein affects the susceptibility to bromadiolone17994578
C021636bromadioloneVKORC1 protein polymorphism results in decreased susceptibility to bromadiolone27117082
C021636bromadioloneVKORC1 protein mutant form results in decreased susceptibility to bromadiolone25847836
C004662chlorophacinoneVKORC1 gene mutant form results in decreased susceptibility to chlorophacinone19752778
C100187chloropicrinchloropicrin results in increased expression of VKORC1 mRNA26352163
D002794Choline[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of VKORC1 gene20938992
D002994ClofibrateClofibrate results in decreased expression of VKORC1 mRNA17585979
D002995Clofibric Acid[Diethylnitrosamine co-treated with Clofibric Acid] affects the expression of VKORC1 mRNA17602206
D003300CopperCopper results in decreased expression of VKORC1 mRNA22465980
D019327Copper SulfateCopper Sulfate results in decreased expression of VKORC1 mRNA19549813
C030123coumarinVKORC1 gene mutant form results in decreased susceptibility to coumarin18278162
C030123coumarinVKORC1 gene mutant form results in increased susceptibility to coumarin18278162
C030123coumarinVKORC1 promoter SNP results in increased susceptibility to coumarin17849045
C004699coumatetralylVKORC1 protein polymorphism results in decreased susceptibility to coumatetralyl27117082
C004699coumatetralylVKORC1 protein polymorphism results in decreased susceptibility to coumatetralyl27117082
D003375Coumestrol"[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of VKORC1 mRNA"19167446
D003375Coumestrol[Coumestrol co-treated with resveratrol] results in increased expression of VKORC1 mRNA19167446
D016572CyclosporineCyclosporine results in decreased expression of VKORC1 mRNA20106945
D003907Dexamethasone[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of VKORC1 mRNA28628672
D003907Dexamethasone[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of VKORC1 mRNA28628672
D003993Dibutyl PhthalateDibutyl Phthalate results in decreased expression of VKORC1 mRNA17379624|2126653
D002945CisplatinCisplatin results in increased expression of VKORC1 mRNA25270620
D004052Diethylnitrosamine[Diethylnitrosamine co-treated with Clofibric Acid] affects the expression of VKORC1 mRNA17602206
C012903difenacoumVKORC1 protein polymorphism results in decreased susceptibility to difenacoum27117082
C012903difenacoumVKORC1 protein polymorphism results in decreased susceptibility to difenacoum27117082
D004997Ethinyl Estradiol[Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of VKORC1 mRNA17942748
D004997Ethinyl EstradiolEthinyl Estradiol results in decreased expression of VKORC1 mRNA17557909
D005047EtoposideEtoposide results in increased expression of VKORC1 mRNA25270620
C082360fipronilfipronil results in decreased expression of VKORC1 mRNA23962444
D005492Folic Acid[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of VKORC1 gene20938992
C069837fullerene C60fullerene C60 results in decreased expression of VKORC1 mRNA19167457
C412815GW 4064GW 4064 promotes the reaction [NR1H4 protein binds to VKORC1 gene]20091679
C492448ICG 001ICG 001 results in increased expression of VKORC1 mRNA26191083
D007213Indomethacin[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of VKORC1 mRNA28628672
D007213Indomethacin[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of VKORC1 mRNA28628672
D007213IndomethacinIndomethacin results in increased expression of VKORC1 mRNA28201806
D015759Ionomycin[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of VKORC1 mRNA25613284
D0150561-Methyl-3-isobutylxanthine[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of VKORC1 mRNA28628672
D0150561-Methyl-3-isobutylxanthine[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of VKORC1 mRNA28628672
C544151jinfukangjinfukang results in increased expression of VKORC1 mRNA27392435
C410337K 7174K 7174 results in decreased expression of VKORC1 mRNA24086573
C079335menadione epoxidemenadione epoxide analog results in decreased activity of VKORC1 protein25499135
D008715Methionine[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of VKORC1 gene20938992
D008748MethylcholanthreneMethylcholanthrene results in increased expression of VKORC1 mRNA18804290
D037742Nanotubes, Carbon"Nanotubes, Carbon analog results in decreased expression of VKORC1 mRNA"25554681|2562005
D037742Nanotubes, Carbon"Nanotubes, Carbon results in decreased expression of VKORC1 mRNA"25554681|2562005
C051752nefazodonenefazodone results in decreased expression of VKORC1 mRNA24136188
C028007nickel monoxidenickel monoxide results in decreased expression of VKORC1 mRNA19167457
D010644PhenprocoumonVKORC1 gene polymorphism affects the susceptibility to Phenprocoumon15536456|1869887
D010644PhenprocoumonVKORC1 intron SNP affects the susceptibility to Phenprocoumon16201835
D010644PhenprocoumonVKORC1 protein polymorphism results in decreased susceptibility to Phenprocoumon17036862
C059514resveratrol[Coumestrol co-treated with resveratrol] results in increased expression of VKORC1 mRNA19167446
D012378RodenticidesVKORC1 protein polymorphism affects the susceptibility to Rodenticides24781908|2719687
D012378RodenticidesVKORC1 protein mutant form results in decreased susceptibility to Rodenticides19890940
D012378RodenticidesVKORC1 protein polymorphism affects the susceptibility to Rodenticides24781908
D012378RodenticidesVKORC1 protein polymorphism results in decreased susceptibility to Rodenticides22888034
C513635S-2-pentyl-4-pentynoic hydroxamic acidS-2-pentyl-4-pentynoic hydroxamic acid results in increased expression of VKORC1 mRNA21427059
D012643Selenium[Selenium co-treated with Vitamin E] results in increased expression of VKORC1 mRNA19244175
D012643SeleniumSelenium results in increased expression of VKORC1 mRNA19244175
D018038Sodium SeleniteSodium Selenite results in decreased expression of VKORC1 mRNA18175754
D013749Tetrachlorodibenzodioxin[Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of VKORC1 mRNA17942748
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of VKORC1 mRNA22298810
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of VKORC1 mRNA21724226
D013755Tetradecanoylphorbol Acetate[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of VKORC1 mRNA25613284
D013853ThioacetamideThioacetamide results in decreased expression of VKORC1 mRNA23411599
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VKORC1 mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of VKORC1 mRNA25979313
D014635Valproic AcidValproic Acid results in increased expression of VKORC1 mRNA23179753|2627250
D014635Valproic AcidValproic Acid results in increased expression of VKORC1 mRNA21427059
D001335Vehicle EmissionsVehicle Emissions results in decreased methylation of VKORC1 gene25560391
D014810Vitamin E[Selenium co-treated with Vitamin E] results in increased expression of VKORC1 mRNA19244175
D014810Vitamin EVitamin E results in increased expression of VKORC1 mRNA19244175
C016186vitamin K1 oxideVKORC1 protein results in increased reduction of vitamin K1 oxide23928358
C016186vitamin K1 oxideWarfarin inhibits the reaction [VKORC1 protein results in increased reduction of vitamin K1 oxide]23928358
C016186vitamin K1 oxideVKORC1 protein affects the reduction of vitamin K1 oxide23928358
C016186vitamin K1 oxideWarfarin inhibits the reaction [VKORC1 protein affects the reduction of vitamin K1 oxide]23928358
D014859WarfarinWarfarin results in increased expression of VKORC1 mRNA25094061
D014859Warfarin[CYP4F2 gene polymorphism co-treated with VKORC1 gene mutant form] affects the susceptibility to Warfarin21084764
D014859WarfarinVKORC1 3' UTR results in decreased susceptibility to Warfarin16676068
D014859WarfarinVKORC1 affects the susceptibility to Warfarin22907842
D014859WarfarinVKORC1 gene affects the susceptibility to Warfarin15630486|1920702
D014859WarfarinVKORC1 gene mutant form affects the susceptibility to Warfarin16879214|2035468
D014859WarfarinVKORC1 gene mutant form results in decreased susceptibility to Warfarin14765194|1826602
D014859WarfarinVKORC1 gene polymorphism affects the abundance of Warfarin25986145
D014859WarfarinVKORC1 gene polymorphism affects the susceptibility to Warfarin15578879|1593041
D014859WarfarinVKORC1 gene polymorphism results in decreased metabolism of Warfarin20073138
D014859WarfarinVKORC1 gene polymorphism results in decreased susceptibility to Warfarin17961434|1803030
D014859WarfarinVKORC1 gene SNP affects the susceptibility to Warfarin20833655|2085480
D014859WarfarinVKORC1 intron polymorphism affects the susceptibility to Warfarin15358623|1852315
D014859WarfarinVKORC1 intron polymorphism results in increased susceptibility to Warfarin16676068
D014859WarfarinVKORC1 intron SNP affects the susceptibility to Warfarin18240904
D014859WarfarinVKORC1 polymorphism affects the susceptibility to Warfarin17510308|2007212
D014859WarfarinVKORC1 promoter polymorphism affects the susceptibility to Warfarin18523153|2257135
D014859WarfarinVKORC1 protein affects the metabolism of Warfarin20073138
D014859WarfarinVKORC1 protein affects the susceptibility to Warfarin17456829|1799597
D014859WarfarinVKORC1 protein polymorphism affects the susceptibility to Warfarin22266406|2380098
D014859WarfarinVKORC1 protein results in increased susceptibility to Warfarin17049586|1711119
D014859WarfarinVKORC1 protein SNP affects the susceptibility to Warfarin23571513
D014859WarfarinVKORC1 results in increased susceptibility to Warfarin20420818
D014859WarfarinVKORC1 SNP affects the susceptibility to Warfarin24966969|2807979
D014859WarfarinWarfarin inhibits the reaction [VKORC1 protein results in increased reduction of vitamin K1 oxide]23928358
D014859WarfarinWarfarin results in decreased activity of VKORC1 protein14765194|1476519
D014859WarfarinVKORC1 gene mutant form results in decreased susceptibility to Warfarin19200363
D014859WarfarinVKORC1 protein polymorphism results in decreased susceptibility to Warfarin27117082
D014859WarfarinVKORC1 gene mutant form results in decreased susceptibility to Warfarin15879509
D014859WarfarinVKORC1 gene SNP affects the susceptibility to Warfarin17009238
D014859WarfarinVKORC1 protein SNP affects the metabolism of Warfarin17009238
D014859WarfarinVKORC1 gene mutant form results in decreased susceptibility to Warfarin14765194|1587950
D014859WarfarinVKORC1 protein mutant form affects the susceptibility to Warfarin23018795
D014859WarfarinVKORC1 protein polymorphism results in decreased susceptibility to Warfarin27117082
D014859WarfarinWarfarin inhibits the reaction [VKORC1 protein affects the reduction of vitamin K1 oxide]23928358
D014859WarfarinVKORC1 gene mutant form results in decreased susceptibility to Warfarin20497562
D014859WarfarinVKORC1 gene polymorphism results in decreased susceptibility to Warfarin19884975
D014859WarfarinVKORC1 protein affects the susceptibility to Warfarin19884975|2049756
D014859WarfarinVKORC1 gene polymorphism affects the susceptibility to Warfarin26469104
D014859WarfarinWarfarin results in decreased activity of VKORC1 protein23710884

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0047057vitamin-K-epoxide reductase (warfarin-sensitive) activity-EXP23918929  
GO:0047057vitamin-K-epoxide reductase (warfarin-sensitive) activity-IDA16270630  
GO:0048038quinone binding-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0007596blood coagulation-IMP16270630  
GO:0017144drug metabolic process-IMP21127708  
GO:0017187peptidyl-glutamic acid carboxylation-IMP20978134  
GO:0042373vitamin K metabolic process-IDA16270630  
GO:0042373vitamin K metabolic process-TAS-  
GO:0055114oxidation-reduction process-IEA-  
GO:0060348bone development-ISS-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005783endoplasmic reticulum-IDA-  
GO:0005789endoplasmic reticulum membrane-TAS-  
GO:0016021integral component of membrane-IEA-  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence
R-HSA-1430728MetabolismTAS
R-HSA-196854Metabolism of vitamins and cofactorsTAS
R-HSA-6806664Metabolism of vitamin KTAS
R-HSA-6806667Metabolism of fat-soluble vitaminsTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
23210243Development and comparison of a new personalized warfarin stable dose prediction algorithm in Chinese patients undergoing heart valve replacement. (2012 Nov)Tan SLPharmazie
21450231Failure of pharmacogenetic-based dosing algorithms to identify older patients requiring low daily doses of warfarin. (2011 Nov)Schwartz JBJ Am Med Dir Assoc
19998810Pharmacogenetics and anticoagulant therapy: two cases of genetically determined response to warfarin. (2009 Sep)Cortez-Dias NRev Port Cardiol
22149257A pharmacokinetic-pharmacodynamic model for predicting the impact of CYP2C9 and VKORC1 polymorphisms on fluindione and acenocoumarol during induction therapy. (2012 Jan 1)Verstuyft CClin Pharmacokinet
26739746A multi-factorial analysis of response to warfarin in a UK prospective cohort. (2016 Jan 6)Bourgeois SGenome Med
17387222Genetic-based dosing in orthopedic patients beginning warfarin therapy. (2007 Sep 1)Millican EABlood
25986145Warfarin Metabolites in Patients Following Cardiac Valve Implantation: A Contribution of Clinical and Genetic Factors. (2015 Jun)Bryk ACardiovasc Drugs Ther
27703968G-1639A but Not C1173T VKORC1 Gene Polymorphism Is Related to Ischemic Stroke and Its Various Risk Factors in Ukrainian Population. (2016)Dubovyk YIBiomed Res Int
23061746Impact of genetic factors (CYP2C9, VKORC1 and CYP4F2) on warfarin dose requirement in the Turkish population. (2013 Mar)Ozer MBasic Clin Pharmacol Toxicol
21766908Development of cocaine-induced interstitial lung damage in two CYP2C and VKORC1 variant allele carriers. (2011 Jun 1)Wijnen PAMol Diagn Ther
23972066Role of the vitamin K epoxide reductase complex subunit 1 (VKORC1) -1639G>A gene polymorphism in patients with retinal vein occlusion. (2013 Dec)Weger MCurr Eye Res
28338108VKORC1-1639 G>A Polymorphism and the Risk of Non-Variceal Upper Gastrointestinal Bleeding. (2017 Mar)Groza IJ Gastrointestin Liver Dis
29776219A simulation of warfarin maintenance dose requirement using a pharmacogenetic algorithm in an ethnically diverse cohort. (2010 May)Gladding PPer Med
24911077CYP2C9, VKORC1, CYP4F2, ABCB1 and F5 variants: influence on quality of long-term anticoagulation. (2014 Apr)Nahar RPharmacol Rep
19032008Pharmacogenomic dosing of warfarin: ready or not? (2008 Aug)Lackner TEConsult Pharm
23800980Factors affecting warfarin dose requirements and quality of anticoagulation in adult Egyptian patients: role of gene polymorphism. (2014 Jun)Bazan NSIr J Med Sci
22629463Therapeutic dosing of acenocoumarol: proposal of a population specific pharmacogenetic dosing algorithm and its validation in north Indians. (2012)Rathore SSPLoS One
20709439Warfarin dosing in patients with impaired kidney function. (2010 Nov)Limdi NAAm J Kidney Dis
21110013Prediction of phenprocoumon maintenance dose and phenprocoumon plasma concentration by genetic and non-genetic parameters. (2011 Apr)Geisen CEur J Clin Pharmacol
26884960VKORC1 and CD-14 genetic polymorphisms associate with susceptibility to cardiovascular and cerebrovascular diseases. (2015)Du JInt J Clin Exp Med
28049362Warfarin Dose Model for the Prediction of Stable Maintenance Dose in Indian Patients. (2018 Mar)Gaikwad TClin Appl Thromb Hemost
25592578Measures of exposure impact genetic association studies: an example in vitamin K levels and VKORC1. (2015)Crawford DCPac Symp Biocomput
21228733Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients. (2011 Mar)Shahin MHPharmacogenet Genomics